glp 1 competitive landscape Obesity GLP-1 Market GLP-1R: Therapeutic Target for Obesity

However, researchers estimate that the lethal dose of GHK-Cu would be about 330 mg/kg of body weight, which is over 300 times larger than its known effective dose

Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations

However, we require creatine via diet

Healthy weight loss requires both